Trial
NCT01743950
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
Genentech, Inc.; National Cancer Institute (NCI)
Condition
Glioma
Intervention
Bevacizumab
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-25